Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

Can Waves of Autoimmune Diseases Occur after the COVID-19 Pandemic?

Author(s): SeyedAhmad SeyedAlinaghi, Pegah Mirzapour and Esmaeil Mehraeen*

Volume 24, Issue 4, 2024

Published on: 19 December, 2023

Article ID: e191223224668 Pages: 2

DOI: 10.2174/0118715265272448231211101718

Price: $65

Graphical Abstract

[1]
SeyedAlinaghi S, Karimi A, Barzegary A, et al. Mucormycosis infection in patients with COVID-19: A systematic review. Health Sci Rep. 2022; 5(2): e529.
[http://dx.doi.org/10.1002/hsr2.529.]
[2]
Mehraeen E, Dadras O, Afsahi AM, et al. Vaccines for COVID-19: A systematic review of feasibility and effectiveness. Infect Disord Drug Targets 2022; 22(2): e230921196758.
[http://dx.doi.org/10.2174/1871526521666210923144837] [PMID: 34554905]
[3]
Qian SZ, Hong W. Lingjie-mao, Chenfeng-lin, Zhendong-fang, Pan JY. Clinical characteristics and outcomes of severe and critical patients with 2019 novel coronavirus disease (COVID-19) in Wenzhou: A retrospective study. Front Med (Lausanne) 2020; 7: 552002.
[http://dx.doi.org/10.3389/fmed.2020.552002] [PMID: 33015108]
[4]
Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells 2021; 10(12): 3592.
[http://dx.doi.org/10.3390/cells10123592] [PMID: 34944099]
[5]
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 2021; 33(2): 155-62.
[http://dx.doi.org/10.1097/BOR.0000000000000776] [PMID: 33332890]
[6]
Jiang J, Zhao M, Chang C, Wu H, Lu Q. Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin Rev Allergy Immunol 2020; 59(2): 248-72.
[http://dx.doi.org/10.1007/s12016-020-08798-2] [PMID: 32557263]
[7]
Bakshi J, Segura BT, Wincup C, Rahman A. Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy Immunol 2018; 55(3): 352-67.
[http://dx.doi.org/10.1007/s12016-017-8640-5] [PMID: 28853005]
[8]
Cheung TT, McInnes IB, Eds. Future therapeutic targets in rheumatoid arthritis? Seminars in immunopathology. Springer 2017.
[9]
Davis LS, Reimold AM. Research and therapeutics—traditional and emerging therapies in systemic lupus erythematosus. Rheumatology 2017; 56 (Suppl. 1): i100-13.
[http://dx.doi.org/10.1093/rheumatology/kew417] [PMID: 28375452]
[10]
Mavragani CP, Moutsopoulos HM. Sjِöِgren’s syndrome: Old and new therapeutic targets. J Autoimmun 2020; 110: 102364.
[http://dx.doi.org/10.1016/j.jaut.2019.102364] [PMID: 31831255]
[11]
Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: Mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 2013; 1(1): 59-70.
[http://dx.doi.org/10.1016/S2213-8587(13)70045-7] [PMID: 24622268]
[12]
Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol 2019; 45(4): 394-412.
[http://dx.doi.org/10.1080/1040841X.2019.1614904] [PMID: 31145640]
[13]
Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses 2019; 11(8): 762.
[http://dx.doi.org/10.3390/v11080762] [PMID: 31430946]
[14]
Winchester NE, Calabrese C, Calabrese L. The intersection of COVID-19 and autoimmunity: What is our current understanding? Pathog Immun 2021; 6(1): 31-54.
[http://dx.doi.org/10.20411/pai.v6i1.417] [PMID: 33969248]
[15]
Ramos-Casals M. Brito-Zerَón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 2021; 17(6): 315-32.
[http://dx.doi.org/10.1038/s41584-021-00608-z] [PMID: 33903743]
[16]
Zacharias H, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of Covid 19. Autoimmun Rev 2021; 20(9): 102883.
[http://dx.doi.org/10.1016/j.autrev.2021.102883] [PMID: 34237419]
[17]
Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-Specific immune response and the pathogenesis of COVID-19. Int J Mol Sci 2022; 23(3): 1716.
[http://dx.doi.org/10.3390/ijms23031716] [PMID: 35163638]
[18]
Hammoudeh SM, Hammoudeh AM, Bhamidimarri PM, et al. Systems immunology analysis reveals the contribution of pulmonary and extrapulmonary tissues to the immunopathogenesis of severe COVID-19 patients. Front Immunol 2021; 12: 595150.
[http://dx.doi.org/10.3389/fimmu.2021.595150] [PMID: 34262555]
[19]
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol 2020; 30(6): 1-9.
[http://dx.doi.org/10.1002/rmv.2141] [PMID: 32845568]
[20]
Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14(3): 898-907.
[http://dx.doi.org/10.1111/cts.12953] [PMID: 33306235]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy